Professor Min Chang-ki was appointed as Vice-Chancellor and Medical Director of Catholic University
Aug 28, 2025
Min Chang-ki (61, baptismal name Iñacio), professor of hematology at Seoul St. Mary's Hospital of Catholic University, was appointed as the 36th Vice-Chancellor and Medical Director of Catholic University. The term of office is two years from September 1, 2025 to August 31, 2027. Min Chang-ki, the new Vice-Chancellor and Medical Director, will oversee the education of Catholic University's medical and nursing colleges and the management of eight affiliated hospitals.
The Catholic Academy (Chairman Chung Soon-taek) of the school decided on such matters at the corporate board meeting on the 21st, and the inauguration ceremony for the vice-president and medical director will be held at Catholic University's omnibus Park on September 1.
Min Chang-ki, the new vice president and medical director, graduated from the Catholic University School of Medicine in 1989 as the nation's top authority on multiple myeloma, plasma cell disease, hematopoietic stem cell transplantation, CAR-T cell and immunotherapy among blood diseases, and is a professor of internal medicine at the Catholic University of Korea after completing his master's degree and doctorate.
In 2002, he conducted training at the bone marrow transplant laboratory at the University of Michigan in the United States, and served as the head of the department of hematology at the Catholic University of Medicine and the head of the medical department at Seoul St. Mary's Hospital. Currently, he has been in important positions such as the head of the planning and coordination department of the Catholic Central Medical Center, the head of the basic medical project promotion team, the head of the Catholic University of Korea's Sungjeong Lifelong Education Center, and the head of the Myeloma Center at Seoul St. Mary's Hospital.
In particular, he has made important achievements and positive influences for the Catholic Central Medical Center's medical advancement in a difficult medical environment at home and abroad, including the opening of Catholic University's omnibus Park, the first one-stop industrial, academic, and research cluster in the single complex in Korea, and the launch of the Catholic Central Medical Center's Basic Medicine Project Promotion Team to integrate basic medicine and clinical medicine, which are essential elements of future medicine in Korea.
Externally, he served as the chairman of the transplant registration committee of the Korean Hematopoietic Cell Transplant Society, the chairman of the Korean Hematopoietic Society's legal director, the chairman of the Multiple Myeloma Research Council, the operating member of the R&D Promotion Headquarters of the Korea Health Industry Promotion Agency, the member management director of the Korean Hematopoietic Society, the expert member of the stem cell treatment evaluation-based research project group, and the secretary-general of the Korean Catholic Medical Association.
In addition, he is currently serving as the president of the Korean Catholic Medical Association, the vice president of the Catholic University School of Medicine, a member of the Health Insurance Review and Assessment Service's cancer disease review committee, and an adviser to the Korean Heart Association's Heart Oncology Research Association.
The Catholic Academy (Chairman Chung Soon-taek) of the school decided on such matters at the corporate board meeting on the 21st, and the inauguration ceremony for the vice-president and medical director will be held at Catholic University's omnibus Park on September 1.
Min Chang-ki, the new vice president and medical director, graduated from the Catholic University School of Medicine in 1989 as the nation's top authority on multiple myeloma, plasma cell disease, hematopoietic stem cell transplantation, CAR-T cell and immunotherapy among blood diseases, and is a professor of internal medicine at the Catholic University of Korea after completing his master's degree and doctorate.
In 2002, he conducted training at the bone marrow transplant laboratory at the University of Michigan in the United States, and served as the head of the department of hematology at the Catholic University of Medicine and the head of the medical department at Seoul St. Mary's Hospital. Currently, he has been in important positions such as the head of the planning and coordination department of the Catholic Central Medical Center, the head of the basic medical project promotion team, the head of the Catholic University of Korea's Sungjeong Lifelong Education Center, and the head of the Myeloma Center at Seoul St. Mary's Hospital.
In particular, he has made important achievements and positive influences for the Catholic Central Medical Center's medical advancement in a difficult medical environment at home and abroad, including the opening of Catholic University's omnibus Park, the first one-stop industrial, academic, and research cluster in the single complex in Korea, and the launch of the Catholic Central Medical Center's Basic Medicine Project Promotion Team to integrate basic medicine and clinical medicine, which are essential elements of future medicine in Korea.
Externally, he served as the chairman of the transplant registration committee of the Korean Hematopoietic Cell Transplant Society, the chairman of the Korean Hematopoietic Society's legal director, the chairman of the Multiple Myeloma Research Council, the operating member of the R&D Promotion Headquarters of the Korea Health Industry Promotion Agency, the member management director of the Korean Hematopoietic Society, the expert member of the stem cell treatment evaluation-based research project group, and the secretary-general of the Korean Catholic Medical Association.
In addition, he is currently serving as the president of the Korean Catholic Medical Association, the vice president of the Catholic University School of Medicine, a member of the Health Insurance Review and Assessment Service's cancer disease review committee, and an adviser to the Korean Heart Association's Heart Oncology Research Association.
|
This article was translated by Naver AI translator.
